United States Patent 10,888,558: Tafenoquine Malaria-Prophylaxis Claims, Patent Scope, and Competitive Landscape
US Patent 10,888,558 protects specific tafenoquine dosing regimens and kits for preventing symptomatic Plasmodium falciparum malaria. Its strongest commercial coverage is the regimen recited in claims 19-22: 200 mg once daily for three days, followed by 200 mg once weekly, with an optional post-exposure dose. The patent does not broadly claim tafenoquine, tafenoquine succinate, or malaria prophylaxis in all dosing forms. It claims defined administration schedules, dose ranges, pharmacokinetic outcomes, patient characteristics, and packaged dose combinations.
The patent is most relevant to Arakoda, the tafenoquine product approved for malaria prophylaxis. It overlaps with the product's labeled three-day loading regimen and weekly maintenance regimen, subject to the patent's additional limitations concerning malaria-naive, G6PD-normal subjects and potential exposure to P. falciparum.
What drug and product does US 10,888,558 cover?
US 10,888,558 covers tafenoquine, including tafenoquine salts and pharmaceutical compositions containing tafenoquine. Claim 12 expressly identifies tafenoquine succinate. The claimed use is prevention of symptomatic P. falciparum malaria in humans.
The patent is directed primarily to:
- Pre-exposure loading doses.
- Weekly or more frequent exposure doses.
- Post-exposure dosing after malaria risk ends.
- Maintenance of a minimum tafenoquine plasma or serum concentration.
- Kits containing loading, exposure, and post-exposure doses.
The claims do not cover every use of tafenoquine. A product or regimen outside the claimed dose ranges, timing, patient population, or exposure context may avoid literal infringement, although doctrine-of-equivalents and dependent-claim issues would require a claim-specific analysis.
Core technical limitations
The principal limitations are:
| Limitation |
Claims affected |
| Prevention of symptomatic P. falciparum malaria |
1, 23 |
| Human subject |
1, 23 |
| Malaria-naive subject |
1, 23 |
| G6PD-normal subject |
1, 23 |
| Tafenoquine or a pharmaceutically acceptable salt |
1, 23 |
| First dose before potential exposure |
1, 23 |
| Two or more initial or primary doses |
1, 23 |
| Weekly or more frequent exposure dosing |
1 |
| Post-exposure dose within 1-10 days after risk ends |
14, 18, 21-23, 33 |
| Minimum tafenoquine concentration of about 80 ng/mL |
7, 8, 16, 25, 26, 32 |
| Oral or sublingual administration |
11, 29 |
| Tafenoquine succinate |
12, 30 |
| Kit containing regimen-specific doses and instructions |
17, 18, 33 |
What are the independent claims in US 10,888,558?
The patent has four principal independent claim categories.
Claim 1: Loading and exposure prophylaxis
Claim 1 requires:
- At least two initial doses.
- At least the first initial dose before potential exposure.
- About 75-299 mg of tafenoquine per initial dose.
- A total of about 500-900 mg across the initial doses.
- Exposure dosing totaling about 75-299 mg per week.
- A malaria-naive, G6PD-normal human subject.
- Prevention of symptomatic P. falciparum malaria.
This claim creates a regimen-level patent position. The total initial-dose limitation is important. Two doses at the lower end of the per-dose range cannot satisfy the 500 mg minimum total. For example, two 75 mg doses total only 150 mg. A two-dose regimen would need to average at least 250 mg per dose, subject to the 299 mg upper limit.
The most commercially important embodiment is three 200 mg initial doses, totaling 600 mg, followed by 200 mg weekly.
Claim 17: Kit for loading and exposure dosing
Claim 17 covers a kit containing:
- One or more initial doses of 75-299 mg.
- Multiple exposure doses totaling 75-299 mg weekly.
- Instructions requiring pre-exposure loading and exposure dosing.
The kit claim can reach the commercial packaging and instructions even where a method-of-use claim presents proof or inducement issues. The claim does not require the same 500-900 mg total loading amount recited in claim 1, creating a potentially broader kit claim in that respect.
Claim 23: Primary and post-exposure dosing
Claim 23 covers:
- Two or more primary doses.
- Each primary dose containing 75-399 mg.
- Primary dosing over approximately 1-21 days.
- At least one primary dose before potential exposure.
- One or more post-exposure doses within 1-10 days after exposure risk ends.
- Each post-exposure dose containing 75-399 mg.
- A malaria-naive, G6PD-normal subject.
Unlike claim 1, claim 23 does not require a weekly exposure-maintenance dose. It is directed to a primary-dose and post-exposure-dose strategy.
Claim 33: Primary and post-exposure kit
Claim 33 covers a kit containing:
- Two or more primary doses of 75-399 mg.
- One or more post-exposure doses of 75-399 mg.
- Instructions for pre-exposure primary dosing and post-exposure dosing within 1-10 days after risk ends.
This claim is commercially relevant to travel packs and fixed-course prophylaxis packages.
Which dependent claims define the commercially important regimen?
Claims 19-22 narrow the broad regimen into a recognizable commercial schedule.
| Claim |
Claimed regimen |
| 19 |
200 mg once daily for three days, then 200 mg once weekly |
| 20 |
First weekly exposure dose seven days after the third loading dose |
| 21 |
200 mg daily for three days, 200 mg weekly, and one post-exposure dose |
| 22 |
First exposure dose seven days after the third loading dose and post-exposure dose seven days after the last exposure dose |
Claim 19 is the central commercial claim. Claims 20-22 add timing limitations that may strengthen validity against prior-art regimens lacking the specified seven-day intervals.
The claim language uses approximate ranges and does not expressly require a particular tablet strength, brand, manufacturer, excipient system, or packaging configuration.
What formulations are protected by US 10,888,558?
The patent protects tafenoquine formulations only when they are used within the claimed methods or supplied in the claimed kits. It is not principally a formulation-composition patent.
Claim 11 covers oral or sublingual administration. Claims 12 and 30 expressly identify tafenoquine succinate. Claims 13 and 31 refer to another salt structure, but the structural depiction is absent from the claim text supplied here. The patent therefore supports coverage of tafenoquine salts, but the exact scope of claim 13 or claim 31 depends on the omitted chemical structure and the patent's specification.
The patent does not, based on the supplied claims, require:
- A particular tablet coating.
- A particular excipient.
- A controlled-release profile.
- A specific particle size.
- A specific dissolution profile.
- A particular manufacturing process.
- A fixed tablet count.
- A specific brand name.
A competitor using tafenoquine succinate in a different tablet formulation could still face infringement risk if the product labeling induces the claimed dosing regimen.
How strong are the pharmacokinetic claims?
Claims 7, 8, 16, 25, 26, and 32 require or describe a minimum tafenoquine concentration of approximately 80 ng/mL.
The claims use two different population thresholds:
- More than 50% of administered individuals.
- At least 95% of the relevant population.
These limitations create both technical and litigation complexity. An infringement analysis would require reliable pharmacokinetic evidence, including:
- Serum or plasma sampling.
- Definition of Cmin.
- Timing relative to initial and exposure doses.
- Tafenoquine analyte measurement.
- Treatment adherence.
- Subject G6PD status.
- Population size and statistical confidence.
- Meaning of "substantially maintain."
Claims with the 95% threshold may be harder to prove than claims based solely on dose and schedule. They may also be more vulnerable to enablement, written-description, indefiniteness, or lack-of-utility challenges if the specification does not adequately support the claimed population-wide pharmacokinetic result.
When does US 10,888,558 lose patent exclusivity?
The patent issued on January 5, 2021. Its ordinary patent term is generally measured as 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.
The patent's expected nominal expiration is in 2038 based on its 2018 nonprovisional filing history, but the exact expiration date must be taken from the USPTO patent-term record. The patent term should not be equated with FDA regulatory exclusivity.
Relevant exclusivity concepts are separate:
| Exclusivity or right |
Relevance |
| Patent term |
Controls enforceable patent rights |
| New chemical entity exclusivity |
Tafenoquine's original FDA exclusivity period |
| Orphan exclusivity |
Depends on the approved indication and sponsor |
| Pediatric exclusivity |
Adds six months only if granted |
| FDA approval of a competing product |
Does not itself invalidate the patent |
| Paragraph IV certification |
May trigger litigation and a 30-month stay |
Tafenoquine was approved in the United States in 2018 for malaria-related indications. The five-year NCE exclusivity period associated with the original active moiety would generally have ended in 2023, absent a different regulatory determination. The patent remains a separate barrier after regulatory exclusivity expires.
What is the Orange Book status of US 10,888,558?
A method-of-use patent may be listed in the FDA Orange Book if it claims an approved method of using the drug and satisfies FDA listing requirements. The practical significance depends on whether the patent is listed against the relevant tafenoquine product and whether an applicant challenges it through a Paragraph IV certification.
The claims in US 10,888,558 are method claims directed to malaria prophylaxis. They are therefore structurally suitable for Orange Book listing against an approved tafenoquine product, but the supplied information does not establish the patent's current listing status, listed expiration date, or the exact NDA against which it is listed.
An ANDA applicant seeking approval for tafenoquine could address the patent through:
- Paragraph I certification, if the patent information is no longer listed.
- Paragraph II certification, if the patent has expired.
- Paragraph III certification, accepting approval after patent expiration.
- Paragraph IV certification, asserting invalidity, unenforceability, or noninfringement.
- A section viii statement, where the applicant omits a patented method from labeling and the remaining label does not encourage the patented use.
Because US 10,888,558 claims malaria prophylaxis dosing, a section viii strategy could be difficult if the proposed product labeling necessarily reproduces the patented regimen.
Which companies are most exposed to this patent?
The primary commercial exposure is associated with products containing tafenoquine succinate and labeled for malaria prophylaxis.
| Company or product category |
Exposure |
| 60 Degrees Pharmaceuticals and Arakoda |
Direct product and labeling overlap |
| Generic tafenoquine developers |
Potential ANDA and inducement risk |
| Other tafenoquine sponsors |
Risk depends on indication and dosing label |
| GSK and Krintafel |
Lower direct overlap because Krintafel is associated with radical cure of P. vivax, not the claimed prophylaxis regimen |
| Non-tafenoquine antimalarial manufacturers |
No direct chemical-product overlap |
Arakoda's three-day loading and weekly dosing concept is closely aligned with claims 19 and 20. Krintafel's approved use is materially different. Krintafel is tafenoquine succinate, but its principal indication is prevention of relapse of P. vivax malaria in patients receiving antimalarial therapy for acute P. vivax infection. That distinction reduces direct method-claim overlap with the P. falciparum prophylaxis claims.
What Paragraph IV challenges or litigation affect the patent?
The supplied record identifies no Paragraph IV notice, ANDA litigation, final court judgment, or settlement agreement involving US 10,888,558.
The likely dispute points for a Paragraph IV challenger would include:
- Anticipation by earlier tafenoquine prophylaxis regimens.
- Obviousness based on known tafenoquine pharmacokinetics and weekly dosing.
- Whether the 80 ng/mL threshold is adequately supported.
- Whether "substantially maintain" is definite.
- Written description for the broad dose and timing ranges.
- Whether the claimed population is sufficiently enabled.
- Noninfringement based on a different loading schedule or labeled indication.
- Noninfringement based on omission of the claimed method from labeling.
The narrower claims could be more defensible against prior art because they combine dose, timing, patient status, exposure context, and pharmacokinetic limitations. The same combination can make infringement proof more demanding.
How does US 10,888,558 compare with other tafenoquine patent rights?
US 10,888,558 is best characterized as a regimen and kit patent.
| Patent-right category |
US 10,888,558 position |
| Tafenoquine molecule |
Not the principal subject |
| Tafenoquine succinate salt |
Included as a claimed salt in method claims |
| Broad malaria treatment |
No; claims are tied to prevention of symptomatic P. falciparum malaria |
| Weekly prophylaxis |
Central subject |
| Three-day loading regimen |
Expressly covered by dependent claims |
| Post-exposure dosing |
Covered by claims 14-15, 18, 21-23, 33 |
| PK target of approximately 80 ng/mL |
Covered by several dependent claims |
| Tablet formulation |
Not claimed as a standalone composition |
| Manufacturing process |
Not claimed in the supplied claims |
| Product packaging |
Covered only through regimen-specific kit claims |
The estate's commercial strength comes from label overlap rather than chemical exclusivity. A competitor that sells the same active ingredient but avoids the patented prophylaxis instructions may reduce method-of-use risk. A competitor that markets a generic product with the same three-day loading and weekly maintenance instructions would face a substantially higher risk profile.
What generic launch scenarios exist?
Launch after patent expiration
A generic applicant can wait for patent expiration and seek approval without contesting validity. This is the lowest litigation-risk path but delays market entry.
Paragraph IV launch
A Paragraph IV applicant could argue that the patent is invalid or not infringed. The strongest potential arguments would likely focus on obviousness of the three-day loading and weekly maintenance schedule, lack of support for the 80 ng/mL pharmacokinetic threshold, and narrow interpretation of the patient and exposure limitations.
Carved-out indication
A generic applicant could attempt a section viii carve-out if it omits the patented P. falciparum prophylaxis method. That strategy would be commercially meaningful only if the remaining approved uses support a viable market and the label does not indirectly encourage the patented regimen.
Alternative dosing
A product using a different dose, loading duration, maintenance interval, or post-exposure schedule may avoid literal infringement. The commercial value of that approach depends on whether the alternative regimen is clinically effective, FDA-approvable, and commercially acceptable.
Key Takeaways
- US 10,888,558 is a tafenoquine regimen and kit patent, not a broad tafenoquine composition patent.
- Claims 19-22 specifically target 200 mg daily for three days followed by 200 mg weekly.
- Claims 1 and 23 divide protection between weekly exposure prophylaxis and primary-plus-post-exposure dosing.
- The claims require a malaria-naive, G6PD-normal human subject.
- Several dependent claims require or describe maintaining tafenoquine concentrations of at least approximately 80 ng/mL.
- Tafenoquine succinate is expressly identified in claims 12 and 30.
- Arakoda is the product with the closest apparent regimen overlap.
- Krintafel has a different principal indication and presents less direct overlap.
- The patent's nominal term extends into 2038 based on its 2018 filing history, subject to USPTO term calculations.
- Generic risk will depend heavily on Orange Book listing, approved labeling, Paragraph IV strategy, and whether a section viii carve-out is commercially workable.
- The supplied record does not establish a Paragraph IV lawsuit, settlement, or final litigation outcome involving this patent.
Frequently Asked Questions
Is US 10,888,558 a tafenoquine composition patent?
No. The supplied claims primarily cover methods of malaria prophylaxis and kits containing regimen-specific tafenoquine doses.
Does the patent cover Arakoda's 200 mg tablet?
The claims do not independently claim a 200 mg tablet as a physical composition. They cover use of tafenoquine in a 200 mg three-day loading and weekly maintenance regimen, and kits containing doses used according to that regimen.
Does the patent cover tafenoquine for P. vivax relapse prevention?
The supplied claims are directed to prevention of symptomatic P. falciparum malaria. They do not expressly claim P. vivax relapse prevention.
Can a generic tafenoquine applicant avoid the patent by changing the dose?
Potentially, if the alternative regimen falls outside every asserted claim and does not induce use of the patented regimen. Dose changes alone may not avoid claims with broad ranges such as 75-399 mg.
Are the 80 ng/mL claims necessary to prove infringement?
No. The patent includes claims based on dose, timing, patient status, and exposure context that do not all require the 80 ng/mL pharmacokinetic limitation. The pharmacokinetic claims create additional, narrower claim positions.
References
-
U.S. Patent No. 10,888,558. (2021). Methods of preventing malaria. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2018). Arakoda prescribing information: Tafenoquine succinate tablets.
-
U.S. Food and Drug Administration. (2018). Krintafel prescribing information: Tafenoquine succinate tablets.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
United States Code, 35 U.S.C. §§ 154, 271, and 355.
